Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy | 15 | 2021 | 1533 | 1.770 |
Why?
|
Rhabdomyosarcoma | 7 | 2021 | 382 | 1.750 |
Why?
|
Radiation Oncology | 8 | 2023 | 555 | 1.610 |
Why?
|
Whole-Body Irradiation | 10 | 2022 | 449 | 1.330 |
Why?
|
Neuroblastoma | 11 | 2019 | 1226 | 1.150 |
Why?
|
Craniopharyngioma | 6 | 2021 | 281 | 1.000 |
Why?
|
Hodgkin Disease | 21 | 2018 | 1415 | 0.970 |
Why?
|
Central Nervous System Neoplasms | 6 | 2022 | 895 | 0.960 |
Why?
|
Bone Neoplasms | 18 | 2023 | 2529 | 0.960 |
Why?
|
Ependymoma | 7 | 2023 | 334 | 0.920 |
Why?
|
Neoplasm Recurrence, Local | 23 | 2023 | 9239 | 0.890 |
Why?
|
Brain Neoplasms | 27 | 2021 | 8863 | 0.780 |
Why?
|
Medulloblastoma | 5 | 2020 | 683 | 0.760 |
Why?
|
Palliative Care | 3 | 2021 | 3493 | 0.730 |
Why?
|
Child | 103 | 2023 | 77709 | 0.690 |
Why?
|
Neoplasms | 14 | 2023 | 21683 | 0.670 |
Why?
|
Pituitary Neoplasms | 5 | 2021 | 1345 | 0.610 |
Why?
|
Leukemia | 4 | 2022 | 1511 | 0.520 |
Why?
|
Child, Preschool | 68 | 2023 | 41006 | 0.510 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 840 | 0.500 |
Why?
|
Neoplasms, Second Primary | 12 | 2021 | 1061 | 0.480 |
Why?
|
Uterine Hemorrhage | 1 | 2015 | 255 | 0.470 |
Why?
|
Hematopoietic Stem Cell Transplantation | 5 | 2022 | 5442 | 0.470 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 11524 | 0.460 |
Why?
|
Facial Neoplasms | 1 | 2014 | 121 | 0.450 |
Why?
|
Combined Modality Therapy | 30 | 2022 | 8642 | 0.440 |
Why?
|
Disease-Free Survival | 27 | 2020 | 6895 | 0.430 |
Why?
|
Adolescent | 82 | 2023 | 85781 | 0.430 |
Why?
|
Radiotherapy Dosage | 21 | 2020 | 2879 | 0.430 |
Why?
|
Vincristine | 14 | 2023 | 1039 | 0.420 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1352 | 0.410 |
Why?
|
Amenorrhea | 1 | 2015 | 485 | 0.410 |
Why?
|
Graft vs Host Disease | 5 | 2022 | 2957 | 0.400 |
Why?
|
Cranial Irradiation | 5 | 2021 | 401 | 0.390 |
Why?
|
Radiosurgery | 6 | 2021 | 1329 | 0.380 |
Why?
|
Sarcoma | 8 | 2022 | 1897 | 0.380 |
Why?
|
Glioma | 7 | 2022 | 3401 | 0.380 |
Why?
|
Ifosfamide | 6 | 2023 | 228 | 0.380 |
Why?
|
Cerebellar Neoplasms | 4 | 2020 | 587 | 0.370 |
Why?
|
Rhabdoid Tumor | 3 | 2008 | 212 | 0.370 |
Why?
|
Germinoma | 2 | 2010 | 133 | 0.350 |
Why?
|
Teratoma | 3 | 2008 | 395 | 0.350 |
Why?
|
Periodicals as Topic | 1 | 2020 | 1432 | 0.340 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2015 | 1205 | 0.340 |
Why?
|
Survival Rate | 24 | 2021 | 12788 | 0.340 |
Why?
|
Radiotherapy, High-Energy | 3 | 2013 | 228 | 0.330 |
Why?
|
Brain Stem Neoplasms | 3 | 2011 | 204 | 0.330 |
Why?
|
Mandibular Neoplasms | 2 | 2023 | 129 | 0.310 |
Why?
|
Infant | 33 | 2023 | 35136 | 0.310 |
Why?
|
Survivors | 7 | 2015 | 2291 | 0.300 |
Why?
|
Photons | 3 | 2020 | 588 | 0.290 |
Why?
|
Spinal Cord Neoplasms | 2 | 2023 | 281 | 0.290 |
Why?
|
Head and Neck Neoplasms | 4 | 2020 | 2734 | 0.290 |
Why?
|
Brachytherapy | 2 | 2014 | 1248 | 0.290 |
Why?
|
Humans | 150 | 2023 | 744343 | 0.280 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 272 | 0.280 |
Why?
|
Retrospective Studies | 47 | 2023 | 77449 | 0.280 |
Why?
|
Treatment Outcome | 37 | 2022 | 63114 | 0.280 |
Why?
|
Preoperative Care | 1 | 2015 | 2250 | 0.280 |
Why?
|
Radiotherapy, Intensity-Modulated | 5 | 2021 | 806 | 0.280 |
Why?
|
Attitude of Health Personnel | 1 | 2020 | 3843 | 0.280 |
Why?
|
Pediatrics | 2 | 2020 | 3475 | 0.270 |
Why?
|
Parents | 1 | 2019 | 3407 | 0.270 |
Why?
|
Dactinomycin | 3 | 2009 | 318 | 0.270 |
Why?
|
Decision Making | 1 | 2019 | 3887 | 0.260 |
Why?
|
Etoposide | 8 | 2023 | 641 | 0.260 |
Why?
|
Neuropilin-1 | 1 | 2005 | 90 | 0.260 |
Why?
|
Male | 103 | 2021 | 350118 | 0.260 |
Why?
|
Female | 100 | 2021 | 380194 | 0.240 |
Why?
|
Soft Tissue Neoplasms | 5 | 2012 | 1363 | 0.240 |
Why?
|
Etanidazole | 1 | 2003 | 26 | 0.230 |
Why?
|
Carcinoma, Mucoepidermoid | 2 | 2019 | 88 | 0.230 |
Why?
|
Particle Accelerators | 3 | 2013 | 173 | 0.220 |
Why?
|
Astrocytoma | 2 | 2005 | 790 | 0.220 |
Why?
|
Radiotherapy, Adjuvant | 12 | 2019 | 1770 | 0.220 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2017 | 4034 | 0.220 |
Why?
|
Follow-Up Studies | 23 | 2020 | 39050 | 0.220 |
Why?
|
Raynaud Disease | 1 | 2003 | 74 | 0.220 |
Why?
|
Radiation Injuries | 6 | 2019 | 1180 | 0.210 |
Why?
|
Doxorubicin | 11 | 2023 | 2234 | 0.210 |
Why?
|
Automobiles | 1 | 2003 | 116 | 0.210 |
Why?
|
Cyclophosphamide | 11 | 2023 | 2242 | 0.210 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2009 | 358 | 0.210 |
Why?
|
Cobalt Radioisotopes | 1 | 2021 | 76 | 0.210 |
Why?
|
Prognosis | 22 | 2022 | 29063 | 0.200 |
Why?
|
Central Nervous System Diseases | 1 | 2006 | 518 | 0.200 |
Why?
|
Neoplasms, Radiation-Induced | 4 | 2013 | 547 | 0.200 |
Why?
|
Translocation, Genetic | 3 | 2017 | 1420 | 0.200 |
Why?
|
Busulfan | 1 | 2022 | 263 | 0.200 |
Why?
|
Young Adult | 32 | 2023 | 56430 | 0.200 |
Why?
|
Adrenal Gland Neoplasms | 3 | 2016 | 740 | 0.200 |
Why?
|
Vibration | 1 | 2003 | 326 | 0.190 |
Why?
|
Quality of Life | 5 | 2023 | 12804 | 0.190 |
Why?
|
Lymphoma | 1 | 2010 | 1877 | 0.190 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2011 | 3760 | 0.190 |
Why?
|
Pelvic Neoplasms | 1 | 2022 | 254 | 0.190 |
Why?
|
Infratentorial Neoplasms | 2 | 2019 | 94 | 0.180 |
Why?
|
Nose Neoplasms | 2 | 2015 | 246 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2019 | 1275 | 0.180 |
Why?
|
Protons | 4 | 2016 | 1127 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 9 | 2020 | 6538 | 0.180 |
Why?
|
Gold | 2 | 2014 | 484 | 0.170 |
Why?
|
3-Iodobenzylguanidine | 2 | 2016 | 115 | 0.170 |
Why?
|
Metal Nanoparticles | 2 | 2014 | 405 | 0.170 |
Why?
|
Diabetes Insipidus | 1 | 2019 | 151 | 0.160 |
Why?
|
Transplantation, Autologous | 4 | 2016 | 2124 | 0.160 |
Why?
|
Free Tissue Flaps | 1 | 2023 | 328 | 0.160 |
Why?
|
Survival Analysis | 16 | 2017 | 10252 | 0.160 |
Why?
|
Adult | 57 | 2023 | 214055 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1519 | 0.160 |
Why?
|
Neuroectodermal Tumors, Primitive | 3 | 2006 | 140 | 0.160 |
Why?
|
Meningeal Neoplasms | 3 | 2021 | 1241 | 0.160 |
Why?
|
Lymphocyte Depletion | 5 | 2002 | 608 | 0.160 |
Why?
|
Bone Marrow Transplantation | 7 | 2008 | 2765 | 0.150 |
Why?
|
Hematologic Diseases | 2 | 2020 | 498 | 0.150 |
Why?
|
Transplantation, Homologous | 4 | 2022 | 4776 | 0.150 |
Why?
|
Femur Head | 1 | 2019 | 301 | 0.150 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 312 | 0.150 |
Why?
|
Neurocytoma | 1 | 2016 | 30 | 0.140 |
Why?
|
Ossification, Heterotopic | 1 | 2019 | 239 | 0.140 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2020 | 1624 | 0.140 |
Why?
|
Tongue Neoplasms | 1 | 2017 | 180 | 0.140 |
Why?
|
Moyamoya Disease | 2 | 2010 | 238 | 0.130 |
Why?
|
Observer Variation | 1 | 2021 | 2593 | 0.130 |
Why?
|
Pelvic Bones | 1 | 2017 | 265 | 0.130 |
Why?
|
Goserelin | 1 | 2015 | 129 | 0.130 |
Why?
|
Salivary Gland Neoplasms | 1 | 2019 | 298 | 0.130 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 2635 | 0.130 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2015 | 56 | 0.130 |
Why?
|
Extremities | 3 | 2017 | 865 | 0.120 |
Why?
|
Occupational Diseases | 1 | 2003 | 1471 | 0.120 |
Why?
|
Prospective Studies | 16 | 2023 | 53288 | 0.120 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5686 | 0.120 |
Why?
|
Cerebral Palsy | 1 | 2019 | 459 | 0.120 |
Why?
|
Radiation Dosage | 2 | 2013 | 1928 | 0.120 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2010 | 286 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2005 | 3508 | 0.120 |
Why?
|
Mandible | 2 | 2023 | 740 | 0.120 |
Why?
|
Clinical Protocols | 2 | 2018 | 1462 | 0.120 |
Why?
|
Brain Stem | 1 | 2019 | 846 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2016 | 3479 | 0.120 |
Why?
|
Contraceptive Agents, Female | 1 | 2015 | 135 | 0.120 |
Why?
|
Leuprolide | 1 | 2015 | 321 | 0.120 |
Why?
|
Vinblastine | 5 | 2018 | 502 | 0.120 |
Why?
|
Neoplasm Staging | 10 | 2017 | 11031 | 0.120 |
Why?
|
Stem Cell Transplantation | 2 | 2016 | 1620 | 0.110 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 4 | 2001 | 906 | 0.110 |
Why?
|
Parotid Neoplasms | 2 | 2006 | 155 | 0.110 |
Why?
|
Remission Induction | 6 | 2005 | 2386 | 0.110 |
Why?
|
Oncolytic Virotherapy | 1 | 2019 | 498 | 0.110 |
Why?
|
Guideline Adherence | 2 | 2017 | 2266 | 0.110 |
Why?
|
Laryngeal Neoplasms | 2 | 2009 | 512 | 0.110 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2013 | 340 | 0.110 |
Why?
|
Pinealoma | 2 | 2008 | 54 | 0.110 |
Why?
|
Nasal Cavity | 1 | 2015 | 313 | 0.110 |
Why?
|
Glioblastoma | 4 | 2010 | 3481 | 0.100 |
Why?
|
Anesthesia | 1 | 2023 | 1561 | 0.100 |
Why?
|
Radiotherapy, Conformal | 2 | 2014 | 548 | 0.100 |
Why?
|
Treatment Failure | 5 | 2017 | 2618 | 0.100 |
Why?
|
Age Factors | 8 | 2017 | 18370 | 0.100 |
Why?
|
Retinoblastoma | 1 | 2013 | 318 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2016 | 2886 | 0.090 |
Why?
|
Anthracyclines | 1 | 2012 | 288 | 0.090 |
Why?
|
Filtration | 1 | 2011 | 234 | 0.090 |
Why?
|
Procarbazine | 4 | 2014 | 181 | 0.090 |
Why?
|
Developing Countries | 2 | 2020 | 2815 | 0.090 |
Why?
|
Recoverin | 1 | 2009 | 13 | 0.090 |
Why?
|
Dose-Response Relationship, Radiation | 4 | 2007 | 876 | 0.090 |
Why?
|
Obesity, Morbid | 1 | 2020 | 1213 | 0.090 |
Why?
|
Prednisone | 5 | 2014 | 1574 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2016 | 2645 | 0.090 |
Why?
|
Disease Management | 1 | 2020 | 2459 | 0.090 |
Why?
|
Antineoplastic Agents | 5 | 2006 | 13695 | 0.090 |
Why?
|
Tumor Burden | 4 | 2019 | 1915 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 2214 | 0.080 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.080 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2008 | 32 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2013 | 604 | 0.080 |
Why?
|
Osteosarcoma | 2 | 2012 | 881 | 0.080 |
Why?
|
Infant, Newborn | 5 | 2021 | 25625 | 0.080 |
Why?
|
Sex Factors | 3 | 2017 | 10397 | 0.080 |
Why?
|
Risk Assessment | 7 | 2021 | 23338 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 2 | 2010 | 2038 | 0.080 |
Why?
|
Hepatoblastoma | 1 | 2008 | 87 | 0.080 |
Why?
|
Risk Factors | 21 | 2021 | 72290 | 0.080 |
Why?
|
Recurrence | 7 | 2023 | 8340 | 0.080 |
Why?
|
Neurofibromatosis 1 | 2 | 2010 | 569 | 0.080 |
Why?
|
Troponin T | 1 | 2012 | 754 | 0.080 |
Why?
|
Incidence | 9 | 2019 | 20947 | 0.080 |
Why?
|
Lung Neoplasms | 5 | 2018 | 13102 | 0.070 |
Why?
|
Mediastinal Neoplasms | 1 | 2010 | 423 | 0.070 |
Why?
|
Pineal Gland | 1 | 2008 | 166 | 0.070 |
Why?
|
Risk | 4 | 2016 | 9687 | 0.070 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2007 | 115 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2008 | 648 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 8 | 2020 | 35421 | 0.070 |
Why?
|
Heart | 2 | 2018 | 4467 | 0.070 |
Why?
|
Time Factors | 11 | 2020 | 40075 | 0.070 |
Why?
|
Myelitis, Transverse | 1 | 2006 | 39 | 0.070 |
Why?
|
Health Care Costs | 1 | 2020 | 3209 | 0.070 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2015 | 1004 | 0.070 |
Why?
|
Quality Assurance, Health Care | 1 | 2017 | 2212 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2012 | 4933 | 0.070 |
Why?
|
Hydromorphone | 1 | 1986 | 65 | 0.070 |
Why?
|
Paranasal Sinus Neoplasms | 2 | 2003 | 234 | 0.060 |
Why?
|
Bleomycin | 2 | 2018 | 512 | 0.060 |
Why?
|
Relative Biological Effectiveness | 2 | 2020 | 323 | 0.060 |
Why?
|
Confidence Intervals | 2 | 2016 | 2971 | 0.060 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2010 | 501 | 0.060 |
Why?
|
Antigens, CD | 4 | 2001 | 4026 | 0.060 |
Why?
|
Algorithms | 2 | 2021 | 13881 | 0.060 |
Why?
|
Mechlorethamine | 2 | 2014 | 136 | 0.060 |
Why?
|
Carboplatin | 2 | 2023 | 801 | 0.060 |
Why?
|
Cerebral Arteries | 1 | 2007 | 494 | 0.060 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2012 | 1573 | 0.060 |
Why?
|
Monte Carlo Method | 3 | 2014 | 1254 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2902 | 0.060 |
Why?
|
Disease Progression | 5 | 2021 | 13284 | 0.060 |
Why?
|
Lung | 2 | 2021 | 9856 | 0.060 |
Why?
|
Societies, Medical | 2 | 2020 | 3743 | 0.060 |
Why?
|
Abdominal Neoplasms | 1 | 2005 | 292 | 0.060 |
Why?
|
Middle Aged | 28 | 2017 | 213383 | 0.060 |
Why?
|
Immunotherapy | 1 | 2019 | 4445 | 0.060 |
Why?
|
Dacarbazine | 2 | 2018 | 566 | 0.060 |
Why?
|
Ovary | 1 | 2007 | 981 | 0.060 |
Why?
|
Myeloablative Agonists | 1 | 2003 | 218 | 0.060 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2017 | 367 | 0.050 |
Why?
|
Chromosomes, Human, Pair 15 | 2 | 2017 | 373 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5137 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2416 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Liver Neoplasms | 2 | 2008 | 4253 | 0.050 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 664 | 0.050 |
Why?
|
Mammography | 1 | 2013 | 2476 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Morphine | 1 | 1986 | 657 | 0.050 |
Why?
|
Proportional Hazards Models | 5 | 2011 | 12354 | 0.050 |
Why?
|
Pulmonary Blastoma | 1 | 2001 | 33 | 0.050 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2012 | 2073 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2011 | 2716 | 0.050 |
Why?
|
Neoplasm Transplantation | 1 | 2005 | 2085 | 0.050 |
Why?
|
Safety | 1 | 2006 | 1186 | 0.050 |
Why?
|
Thalidomide | 1 | 2006 | 890 | 0.050 |
Why?
|
Substance Withdrawal Syndrome | 1 | 1986 | 632 | 0.050 |
Why?
|
Optic Chiasm | 2 | 2014 | 87 | 0.050 |
Why?
|
Gene Dosage | 1 | 2005 | 1252 | 0.050 |
Why?
|
Organs at Risk | 2 | 2014 | 346 | 0.050 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2020 | 26 | 0.050 |
Why?
|
Sacrum | 1 | 2022 | 288 | 0.050 |
Why?
|
Central Nervous System | 2 | 2021 | 1357 | 0.050 |
Why?
|
Thyroid Neoplasms | 1 | 2014 | 2282 | 0.050 |
Why?
|
Hemangioendothelioma | 1 | 2021 | 121 | 0.050 |
Why?
|
Lymphocyte Transfusion | 1 | 2001 | 236 | 0.050 |
Why?
|
Methotrexate | 4 | 2012 | 1727 | 0.050 |
Why?
|
Orthopedic Procedures | 1 | 2010 | 1288 | 0.050 |
Why?
|
Ribonuclease III | 1 | 2022 | 275 | 0.050 |
Why?
|
HIV | 4 | 1987 | 1604 | 0.050 |
Why?
|
Sweden | 1 | 2003 | 1345 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2012 | 5097 | 0.040 |
Why?
|
Echocardiography | 1 | 2012 | 5102 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2010 | 6365 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2005 | 987 | 0.040 |
Why?
|
Neuroectodermal Tumors | 1 | 1999 | 27 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2020 | 403 | 0.040 |
Why?
|
Lymphatic Abnormalities | 1 | 2021 | 133 | 0.040 |
Why?
|
Neoplasm Metastasis | 4 | 2016 | 4851 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2022 | 375 | 0.040 |
Why?
|
Quality Control | 1 | 2021 | 841 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2004 | 1364 | 0.040 |
Why?
|
Mice, Nude | 1 | 2005 | 3689 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 2 | 1997 | 1838 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2017 | 5319 | 0.040 |
Why?
|
Cohort Studies | 5 | 2021 | 40561 | 0.040 |
Why?
|
Thymidine Kinase | 1 | 2019 | 290 | 0.040 |
Why?
|
Blood Pressure | 1 | 2014 | 8554 | 0.040 |
Why?
|
Bone Transplantation | 1 | 2023 | 907 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2019 | 12245 | 0.040 |
Why?
|
Sarcoma, Kaposi | 1 | 2021 | 370 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4751 | 0.040 |
Why?
|
Aged | 17 | 2017 | 163280 | 0.040 |
Why?
|
Hand | 1 | 2003 | 884 | 0.040 |
Why?
|
Blotting, Western | 1 | 2005 | 5179 | 0.040 |
Why?
|
Cardiovascular Diseases | 3 | 2014 | 15165 | 0.040 |
Why?
|
Prednisolone | 1 | 2018 | 334 | 0.040 |
Why?
|
Heart Diseases | 1 | 2010 | 2788 | 0.040 |
Why?
|
Prodrugs | 1 | 2019 | 268 | 0.040 |
Why?
|
Community Mental Health Services | 1 | 2000 | 386 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 5 | 2018 | 20129 | 0.040 |
Why?
|
Regression Analysis | 1 | 2007 | 6459 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2023 | 5078 | 0.040 |
Why?
|
AIDS-Related Complex | 2 | 1986 | 110 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2013 | 14722 | 0.040 |
Why?
|
Aged, 80 and over | 9 | 2014 | 57776 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 624 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2001 | 607 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9274 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2011 | 5221 | 0.030 |
Why?
|
Cisplatin | 2 | 2015 | 1662 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2011 | 4256 | 0.030 |
Why?
|
Histocompatibility | 1 | 1997 | 330 | 0.030 |
Why?
|
Boston | 4 | 2010 | 9313 | 0.030 |
Why?
|
Vascular Malformations | 1 | 2021 | 454 | 0.030 |
Why?
|
Laparoscopy | 1 | 2007 | 2151 | 0.030 |
Why?
|
Incidental Findings | 2 | 2011 | 689 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1643 | 0.030 |
Why?
|
Neoadjuvant Therapy | 3 | 2013 | 2728 | 0.030 |
Why?
|
Topotecan | 1 | 2015 | 137 | 0.030 |
Why?
|
Adenoviridae | 1 | 2019 | 1099 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 9438 | 0.030 |
Why?
|
Erythropoietin | 1 | 1998 | 726 | 0.030 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1987 | 2232 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2013 | 20822 | 0.030 |
Why?
|
Rare Diseases | 1 | 2018 | 553 | 0.030 |
Why?
|
Prevalence | 2 | 2015 | 15226 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 513 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2003 | 1796 | 0.030 |
Why?
|
Hip Joint | 1 | 2019 | 1002 | 0.030 |
Why?
|
SEER Program | 1 | 2017 | 1508 | 0.030 |
Why?
|
Heart Function Tests | 1 | 2012 | 330 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11366 | 0.030 |
Why?
|
Viral Proteins | 1 | 2019 | 1900 | 0.020 |
Why?
|
Radiodermatitis | 1 | 2011 | 60 | 0.020 |
Why?
|
Pituitary Gland | 1 | 2014 | 665 | 0.020 |
Why?
|
International Cooperation | 1 | 2018 | 1420 | 0.020 |
Why?
|
Cause of Death | 2 | 2017 | 3584 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2959 | 0.020 |
Why?
|
Cerebral Cortex | 1 | 2007 | 5708 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2014 | 1032 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15295 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2531 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1859 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 224 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2014 | 2031 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2014 | 826 | 0.020 |
Why?
|
Femur | 1 | 2016 | 1297 | 0.020 |
Why?
|
Epiglottis | 1 | 2009 | 79 | 0.020 |
Why?
|
Skin | 2 | 2014 | 4364 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2005 | 10481 | 0.020 |
Why?
|
Computer-Aided Design | 1 | 2011 | 298 | 0.020 |
Why?
|
Nausea | 1 | 2012 | 673 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2019 | 3420 | 0.020 |
Why?
|
Mesna | 1 | 2008 | 66 | 0.020 |
Why?
|
Mediastinum | 1 | 2010 | 267 | 0.020 |
Why?
|
Intelligence | 1 | 2014 | 920 | 0.020 |
Why?
|
Vomiting | 1 | 2012 | 636 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 16689 | 0.020 |
Why?
|
Secondary Prevention | 2 | 2008 | 1530 | 0.020 |
Why?
|
Anemia | 1 | 1998 | 1506 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2011 | 868 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2019 | 21746 | 0.020 |
Why?
|
Medical Oncology | 1 | 2020 | 2265 | 0.020 |
Why?
|
Limb Salvage | 1 | 2010 | 433 | 0.020 |
Why?
|
Glottis | 1 | 2009 | 217 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 648 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3616 | 0.020 |
Why?
|
T-Lymphocytes | 3 | 2001 | 10180 | 0.020 |
Why?
|
Tissue Donors | 1 | 1997 | 2240 | 0.020 |
Why?
|
Supratentorial Neoplasms | 1 | 2008 | 160 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7186 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 10943 | 0.020 |
Why?
|
Skin Transplantation | 1 | 2012 | 1074 | 0.020 |
Why?
|
Deltaretrovirus Infections | 1 | 1986 | 26 | 0.020 |
Why?
|
Circle of Willis | 1 | 2007 | 68 | 0.020 |
Why?
|
Melphalan | 1 | 2008 | 431 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 895 | 0.020 |
Why?
|
Life Tables | 2 | 1997 | 370 | 0.020 |
Why?
|
Splenectomy | 1 | 2008 | 395 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2019 | 2987 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1670 | 0.020 |
Why?
|
Mutation | 2 | 2022 | 29786 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9146 | 0.020 |
Why?
|
Neuralgia | 1 | 2012 | 570 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 693 | 0.020 |
Why?
|
Polysomnography | 1 | 2012 | 1776 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 1359 | 0.020 |
Why?
|
HIV Infections | 1 | 2011 | 16718 | 0.020 |
Why?
|
Hepatectomy | 1 | 2008 | 550 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2003 | 15540 | 0.020 |
Why?
|
Drug Therapy | 1 | 2008 | 497 | 0.020 |
Why?
|
Perineum | 1 | 1986 | 211 | 0.020 |
Why?
|
Lower Extremity | 1 | 2012 | 1158 | 0.020 |
Why?
|
Chromosomes, Human, 19-20 | 1 | 2003 | 12 | 0.020 |
Why?
|
Chromosomes, Human, 13-15 | 1 | 2003 | 52 | 0.020 |
Why?
|
Metabolome | 1 | 2011 | 895 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1486 | 0.010 |
Why?
|
Surgical Flaps | 1 | 2012 | 1640 | 0.010 |
Why?
|
Burkitt Lymphoma | 1 | 1986 | 327 | 0.010 |
Why?
|
Breast | 1 | 2013 | 1969 | 0.010 |
Why?
|
Fluorouracil | 1 | 2008 | 1619 | 0.010 |
Why?
|
Pilot Projects | 1 | 2017 | 8324 | 0.010 |
Why?
|
Age of Onset | 1 | 2010 | 3271 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2001 | 5181 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 9959 | 0.010 |
Why?
|
Autopsy | 1 | 2007 | 1020 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2009 | 2649 | 0.010 |
Why?
|
Lymphoproliferative Disorders | 1 | 1986 | 523 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1998 | 3523 | 0.010 |
Why?
|
Equipment Design | 1 | 2011 | 3582 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12720 | 0.010 |
Why?
|
Carcinoma in Situ | 1 | 2008 | 806 | 0.010 |
Why?
|
Logistic Models | 2 | 2011 | 13408 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2014 | 3778 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1850 | 0.010 |
Why?
|
Ribs | 1 | 2003 | 252 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 2002 | 257 | 0.010 |
Why?
|
Hippocampus | 1 | 2014 | 3675 | 0.010 |
Why?
|
Wound Healing | 1 | 2012 | 2785 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 2001 | 378 | 0.010 |
Why?
|
Graft vs Tumor Effect | 1 | 2001 | 72 | 0.010 |
Why?
|
RNA, Viral | 2 | 1986 | 2902 | 0.010 |
Why?
|
Kidney Neoplasms | 1 | 2018 | 4262 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 3 | 1986 | 1375 | 0.010 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2008 | 1101 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 6993 | 0.010 |
Why?
|
Mental Disorders | 1 | 2000 | 6600 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 1993 | 3386 | 0.010 |
Why?
|
Spine | 1 | 2007 | 1144 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2015 | 4245 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Mice | 2 | 2005 | 81183 | 0.010 |
Why?
|
Lymphocyte Subsets | 1 | 2001 | 315 | 0.010 |
Why?
|
Stroke Volume | 1 | 2012 | 5007 | 0.010 |
Why?
|
Blood Component Removal | 1 | 2000 | 125 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3086 | 0.010 |
Why?
|
Crime | 1 | 2000 | 215 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.010 |
Why?
|
Blast Crisis | 1 | 1998 | 103 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2003 | 1677 | 0.010 |
Why?
|
Artificial Intelligence | 1 | 2011 | 2214 | 0.010 |
Why?
|
Bone Marrow Purging | 1 | 1997 | 109 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6196 | 0.010 |
Why?
|
Lymphatic Irradiation | 1 | 1997 | 103 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 2002 | 0.010 |
Why?
|
Cognition | 1 | 2014 | 6770 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 1998 | 666 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5102 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2008 | 4560 | 0.010 |
Why?
|
Platelet Count | 1 | 1998 | 781 | 0.010 |
Why?
|
Smoking | 1 | 2013 | 8987 | 0.010 |
Why?
|
Research Design | 1 | 2011 | 5987 | 0.010 |
Why?
|
Cytarabine | 1 | 1997 | 692 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1986 | 3474 | 0.010 |
Why?
|
Models, Biological | 1 | 2011 | 9583 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19905 | 0.010 |
Why?
|
Pneumonia | 1 | 1986 | 2133 | 0.010 |
Why?
|
Animals | 2 | 2005 | 168757 | 0.010 |
Why?
|
Graft Survival | 2 | 1997 | 3737 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2014 | 6487 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8480 | 0.010 |
Why?
|
Social Behavior | 1 | 2000 | 1127 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1997 | 692 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2453 | 0.010 |
Why?
|
Outpatients | 1 | 2000 | 1486 | 0.010 |
Why?
|
Brain | 1 | 2019 | 26385 | 0.010 |
Why?
|
Comorbidity | 1 | 2007 | 10388 | 0.010 |
Why?
|
Melanoma | 1 | 2010 | 5510 | 0.010 |
Why?
|
Hemoglobins | 1 | 1998 | 1534 | 0.010 |
Why?
|
HLA Antigens | 1 | 1997 | 1381 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1998 | 1179 | 0.010 |
Why?
|
Radiography | 1 | 2001 | 7023 | 0.010 |
Why?
|
Transplantation Conditioning | 1 | 1997 | 1598 | 0.010 |
Why?
|
Patient Compliance | 1 | 2000 | 2684 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 12745 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1993 | 1588 | 0.010 |
Why?
|
United States | 2 | 2009 | 69872 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2001 | 4386 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1998 | 6622 | 0.000 |
Why?
|
Erythrocyte Transfusion | 1 | 1993 | 565 | 0.000 |
Why?
|
Deltaretrovirus | 1 | 1986 | 170 | 0.000 |
Why?
|
Spleen | 1 | 1993 | 2362 | 0.000 |
Why?
|
Acute Disease | 1 | 1997 | 7149 | 0.000 |
Why?
|
Autoradiography | 1 | 1986 | 745 | 0.000 |
Why?
|
Hematologic Neoplasms | 1 | 1997 | 1832 | 0.000 |
Why?
|
Opportunistic Infections | 1 | 1986 | 389 | 0.000 |
Why?
|
Genotype | 1 | 1997 | 12951 | 0.000 |
Why?
|
Pulmonary Fibrosis | 1 | 1986 | 530 | 0.000 |
Why?
|
Cell Movement | 1 | 1993 | 5217 | 0.000 |
Why?
|
Hospitalization | 1 | 2000 | 10262 | 0.000 |
Why?
|
Mice, Inbred C57BL | 1 | 1993 | 21827 | 0.000 |
Why?
|